Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1995 Jul;121(7):387–392. doi: 10.1007/BF01212943

Monoclonal antibodies against native ovarian tumor cells: specificity and characterization of the antigen. A preliminary report

Lina Wasserman 1,✉, Alexander Neri 2,3, Bari Kaplan 2,3, Yoram Manor 2, Michal Galli 1, Britta Hardy 1
PMCID: PMC12200422  PMID: 7543483

Abstract

Monoclonal antibodies were prepared against native human ovarian carcinoma cells derived from the ascitic fluid of a patient (BH). One antibody, HC7R7, was selected on the basis of its binding to tumor BH cells, to other ovarian tumor cell lines (CAOV-3 and GZL-8), but not to the patient's fibroblasts. One hundred cell smears from ascitic and pleural effusions of tumor-suspected patients were immunostained with HC7R7. All serous ovarian carcinomas and half of the breast carcinomas stained positive with HC7R7; cells from noncancer ovarian aspirates were negative. Mesothelial cells were also stained with HC7R7. A correlation was noted between HC7R7 and OC-125 staining of ovarian tumor cells but not between HC7R7 and c-neu staining of breast tumor paraffin sections. The location of HC7R7-positive material in ovarian tumor cell lines (CAOV-3 and GZL-8) differed from that in the breast tumor cell line (MCF-7). CAOV-3 and GZL-8 showed membrane binding while, in MCF-7, not fully identified intracellular organelles were stained. Sodium dodecyl sulfate/polyacrylamide gel electrophoresis and immunoblots from membrane and cytosol fractions of GZL-8 and MCF-7 showed HC7R7 binding to three protein bands in the membrane fraction and to three other bands in the cytosol, all in the 29- to 68-kDa range. Two of the bands were glycoproteins. The only band that was different in the GZL-8 and MCF-7 cells was a 43-kDa glycoprotein, which was more pronounced in the MCF-7 cells. The possible significance of the new HC7R7 antibodies for detection and survey of ovarian malignancies is discussed.

Key words: Ovarian cancer, Breast cancer, Monoclonal antibodies, Malignant effusions, Immunostaining

References

  1. Andrews AT (1988) In: Peacocke AR, Harnington WF (eds) Electrophoresis theory, techniques and biochemical and clinical applications, 2nd edn Clarendon, Oxford, pp 5–78 [Google Scholar]
  2. Bast RC Jr, Feeney M, Lazarus M, Nadler L, Colvin RB, Knapp RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Ivest 68: 1331–1337 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chang K, Pai LH, Batra JK, Pastan I, Willingham MC (1992a) Characterization of the antigen (CAKI) recognized by monoclonal antibody KI present on ovarian cancers and normal mesothelium. Cancer Res 52: 181–186 [PubMed] [Google Scholar]
  4. Chang K, Pastan I, Willingham MC (1992b) Isolation and characterization of a monoclonal antibody KI reactive with ovarian cancers and normal mesothelium. Int J Cancer 50: 373–381 [DOI] [PubMed] [Google Scholar]
  5. Glassy MC, Surth CD (1985) Immunodetection of cell bound antigen using both mouse and human monoclonal antibodies. J Immunol Methods 81: 115–122 [DOI] [PubMed] [Google Scholar]
  6. Jett M, Seed TM, Jamieson GA (1972) Isolation and characterization of plasma membranes and intact nuclei from lymphoid cells. J Biol Chem 252: 2134–2142 [PubMed] [Google Scholar]
  7. Kabawat SE, Bast RC Jr, Bhan AK, Welch WR, Knapp RC, Colvin RB (1983) Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC-125. Int J Gynecol Pathol 2: 275–285 [DOI] [PubMed] [Google Scholar]
  8. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497 [DOI] [PubMed] [Google Scholar]
  9. Kurrasch RH, Rutherford AV, Rick ME, Gallo MG, Lovelace ET, Pastan I, Willingham MC (1989) Characterization of monoclonal antibody, OVBI, which binds to a unique determinant in human ovarian carcinomas and myeloid cells. J Histochem Cytochem 37: 56–67 [DOI] [PubMed] [Google Scholar]
  10. Laemmli VK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685 [DOI] [PubMed] [Google Scholar]
  11. Levi J, King RJB (1990) GTP analogues cause preferential translocation of an 18 kDa cytosolic G-protein to the membrane fraction in the ZR-75-1 human breast cancer cell line. Biochem J 271: 223–229 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Manor Y, Shneyour Y, Nordenberg J, Levavi H, Ovadia J, Novogrodsky A, Wasserman L (1992) The effect of sodium butyrate, interferon-α and verapamil on the sensitivity of ovarian carcinoma cells to Adriamycin. Cancer J 5: 101–106 [Google Scholar]
  13. Masuho Y, Zalutsky M, Knapp RC, Bast RC Jr (1984) Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Cancer Res 44: 2813–2819 [PubMed] [Google Scholar]
  14. Miotti S, Canevari S, Menard S, Mezzanzanica D, Porro G, Pupa SM, Regazzoni M, Tagliabue E, Colnaghi MJ (1987) Characterization of human ovarian carcinoma-associated agents defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 39: 297–303 [DOI] [PubMed] [Google Scholar]
  15. Nouwen EJ, Hendrix PG, Dauwe S, Eerdekens MW, De Broe ME (1987) Tumor markers in the human ovary and its neoplasms. Am J Pathol 126: 230–242 [PMC free article] [PubMed] [Google Scholar]
  16. Wasserman L, Aviram R, Levavi H, Ovadia J, Shneyour Y, Frisch A, Blau O, Beery E, Novogrodsky A, Nordenberg J (1992) A cell line with unusual characteristics from an ovarian carcinoma patient: modulation of sensitivity to antitumor drugs. Eur J Cancer 28: 22–27 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES